Please use this identifier to cite or link to this item:
Title: SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
Authors: Vera, R
Dotor, E
Feliu, J
González, E
Laquente, B
Macarulla, T
Martínez, E
Maurel, J
Salgado, M
Manzano, J L
metadata.dc.contributor.authoraffiliation: [Vera,R] Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain. [Dotor,E] Consorcio Sanitario de Terrassa, Barcelona, Spain. [Feliu,J] Hospital Universitario la Paz, Madrid, Spain. [González,E] Complejo Hospitalario Universitario de Granada Virgen de las Nieves, Granada, Spain. [Laquente,B] ICO-Hospitalet de LLobregat, Hospital Duran i Reynals, Hospitalet de Llobregat, Spain. [Macarulla,T] Hospital Vall`Hebron, Barcelona, Spain. [Martínez,E] Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Maurel,J] Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Salgado,M] Complexo Hospitalario de Orense (CHUO), Ourense, Spain. [Manzano,JL] ICO-Badalona, Hospital Germans Trias i Pujol, Barcelona, Spain.
Keywords: Pancreatic cancer;Treatment;Diagnostic;Guidelines;Neoplasias pancreáticas;Guías de práctica clínica como asunto;Factores de riesgo;España;Humanos
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms
Medical Subject Headings::Health Care::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors
Medical Subject Headings::Geographicals::Geographic Locations::Europe::Spain
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Issue Date: Dec-2016
Publisher: Springer Verlag
Citation: Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, et al. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol. 2016 ; 18(12):1172-1178
Abstract: Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.
Description: Journal Article;
metadata.dc.identifier.doi: 10.1007/s12094-016-1586-x
ISSN: 1699-3055 (Online)
1699-048X (Print)
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
Vera_SEOMClinicalGuideline.pdfArtículo publicado409,19 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons